Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 5/20 | 0.32 |
| ▸ | CTSK | P43235 | 2/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
| ▸ | CTSC | P53634 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 2/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7428125 | 0.68 | DRD4 (0.47) | MEN1KMT2ADRD4DRD2DRD3 | |
| SCHEMBL4424637 | 0.66 | MEN1 (0.40) | MEN1KMT2ACTSSCTSKCTSL | |
| SCHEMBL8670850 | 0.64 | MAOA (0.38) | MEN1KMT2ACTSCCYP19A1CYP11B1 | |
| SCHEMBL8528073 | 0.63 | TDP1 (0.48) | — | |
| SCHEMBL7266929 | 0.62 | DRD4 (0.45) | DRD4 | |
| SCHEMBL8935841 | 0.61 | TSHR (0.48) | MEN1KMT2A | |
| SCHEMBL10042379 | 0.59 | RIPK1 (0.46) | MEN1KMT2A | |
| SCHEMBL27569840 | 0.59 | TDP1 (0.46) | — | |
| SCHEMBL28715513 | 0.59 | CA1 (0.48) | — | |
| SCHEMBL7859396 | 0.59 | LTA4H (0.56) | MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1973404-B1 | MALONONITRILE COMPOUNDS | MERIAL INC (US) | 2015-10-28 | — | — | EP | claimed |
| US-20090326012-A1 | Malononitrile Compounds | MERIAL, INC. | 2009-12-31 | — | — | US | claimed |
| EP-1973404-B1 | MALONONITRILE COMPOUNDS | MERIAL INC (US) | 2015-10-28 | — | — | EP | disclosed |
| US-5648370-A | 7-(2-aminoethyl) benzothiazolones | ASTRA PHARMACEUTICALS LIMITED (GB) | 1997-07-15 | — | — | US | disclosed |
| WO-1993023385-A1 | BIOLOGICALLY ACTIVE AMINES | FISONS PLC (GB) | 1993-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326012-A1 | Malononitrile Compounds | NR0B2, NR2C2, NR0B1 | MEN1 3641/4885KMT2A 3154/4885CTSS 2342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.